Astria Therapeutics, Inc. (ATXS) Tops Q3 EPS by 16c; Reports Cash and Cash Equivalents of $131.8M

Astria Therapeutics, Inc. (NASDAQ: ATXS) reported Q3 EPS of ($0.61), $0.16 better than the analyst estimate of ($0.77).

For earnings history and earnings-related data on Astria Therapeutics, Inc. (ATXS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15